National Health Act 1953 - Amendment determination under paragraph 98C(1)(b) - conditions (No. PB 38 of 2009)

Overview

The National Health Act 1953, as amended by the National Health Amendment Determination under paragraph 98C(1)(b) in 2009, addresses the need for timely and affordable access to a broad range of medicines for all Australians. This legislation is instrumental in establishing the Pharmaceutical Benefits Scheme (PBS), which ensures that Australians can access essential medications at a reasonable cost. The amendments introduced by the 2009 Determination focus on updating the conditions under which payments will be made by the Commonwealth for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners. This was achieved by modifying the existing legislative instrument to include new forms of medications, such as modified release tablets of hydromorphone, thereby expanding the range of pharmaceutical benefits available under the PBS. The determination was made by the Minister for Health, following consultations with the Pharmaceutical Benefits Advisory Committee, and came into effect on 1 May 2009.

Scope and Application

The National Health Act 1953 Amendment Determination under paragraph 98C(1)(b) applies to the Pharmaceutical Benefits Scheme (PBS), which is administered by the Commonwealth to ensure all Australians have access to reliable, timely, and affordable medicines. This legislation governs the conditions under which payments are made for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners. It sets out the specific forms and brands of listed drugs that qualify for benefits, as determined by the Minister, and establishes the responsible person for each pharmaceutical item. The Act applies to a wide range of entities, including individuals, pharmaceutical companies, healthcare providers, and the Commonwealth government. The geographic reach of this Act is national, applying across Australia. There are no exclusions, exemptions, or thresholds specified in the Act itself, though these may be defined in subordinate instruments. The Act allows for its application to be extended or restricted through additional legislative instruments, which detail specific conditions and amendments as necessary.

Key Provisions

The main operative sections of this legislation pertain to the Pharmaceutical Benefits Scheme (PBS) under Part VII of the National Health Act 1953. Specifically, section 85(1) mandates that the Commonwealth provides pharmaceutical benefits to Australians, with the exact nature and scope of these benefits determined by the Minister through legislative instruments. Subsection 85(2) clarifies that drugs and medicinal preparations included in the PBS are declared by the Minister, with subsection 84(1) defining these as listed drugs. Additionally, the Minister has the authority to determine the form, administration manner, and specific brands of these listed drugs through subsections 85(3), 85(5), and 85(6) respectively. The amendments made by this instrument, particularly those outlined in Schedule 1, update the conditions under which payments will be made for the supply of these pharmaceutical benefits by approved pharmacists and medical practitioners, as provided under section 98C(1)(b). The Act imposes several obligations on the parties involved. The Minister must consult with the Pharmaceutical Benefits Advisory Committee (PBAC), which includes representatives from various relevant sectors, to recommend which medicines should be subsidised through the PBS. This ensures that the decisions made are well-rounded and consider various perspectives. Furthermore, the Minister's determinations regarding the form, administration, and brands of listed drugs must be made in accordance with the legislative provisions outlined above. Approved pharmacists and medical practitioners must adhere to these conditions to be eligible for Commonwealth payments for the supply of pharmaceutical benefits. There are no specific offences, penalties, or consequences outlined in the provided text for breaches of the Act or its amendments. However, the nature of the legislation implies that non-compliance with the Minister's determinations and the conditions set forth could potentially lead to legal ramifications. These might include civil or administrative penalties for entities or individuals who fail to comply with the stipulated requirements for the supply of pharmaceutical benefits. The exact penalties would depend on the specific circumstances and any additional legislation that may provide further detail on enforcement and compliance mechanisms.